AR008371A1 - AN ADDITION SALT WITH ACID OF A 10-AMINOALIFATIL-DIBENZ [B, F], OXEPINE, YOUR EMPLOYMENT; PROCEDURE FOR ITS PREPARATION, A 10-AMINOALIFATIL-DIBENZ [B, F] OXEPINE, A PHARMACEUTICAL PREPARATION CONTAINING SUCH SALT OR SUCH OXEPINE AND A PROCEDURE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - Google Patents

AN ADDITION SALT WITH ACID OF A 10-AMINOALIFATIL-DIBENZ [B, F], OXEPINE, YOUR EMPLOYMENT; PROCEDURE FOR ITS PREPARATION, A 10-AMINOALIFATIL-DIBENZ [B, F] OXEPINE, A PHARMACEUTICAL PREPARATION CONTAINING SUCH SALT OR SUCH OXEPINE AND A PROCEDURE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

Info

Publication number
AR008371A1
AR008371A1 ARP970102247A ARP970102247A AR008371A1 AR 008371 A1 AR008371 A1 AR 008371A1 AR P970102247 A ARP970102247 A AR P970102247A AR P970102247 A ARP970102247 A AR P970102247A AR 008371 A1 AR008371 A1 AR 008371A1
Authority
AR
Argentina
Prior art keywords
oxepine
dibenz
procedure
aminoalifatil
salts
Prior art date
Application number
ARP970102247A
Other languages
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR008371A1 publication Critical patent/AR008371A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/14—[b,f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Se refiere a sales de adicion con ácidos de 10-aminoalifatil-dibenz[b,f] oxepina de la formula (I), en la que alk es un radical alifático bivalente, Res un grupo amino insubstituido, monosubstituido o disubstituido por radicales alifáticos y/o aralifáticos monovalentes o bien disubstituido por radicalesalifáticos o aralifáticos bivalentes y R1, R2, R3 y R4 independientemente entre ellos denotan hidrogeno, alquilo inferior, alcoxi inferior, halogeno otrifluorometilo, con ácidos carboxílicos orgánicos. Dichas sales pueden ser utilizadas como substancias activas para medicinas antineurodegenerativas.También se refiere a los nuevos compuestos de la formula (I) en su forma libre, al empleo de dichas sales, a un procedimiento para elaborarlas, apreparaciones farmacéuticas que contienen dichas sales o compuestos de formula (I) en su forma libre y a un procedimiento para el tratamiento deenfermedades neurodegenerativas mediante dichas sales o compuestos de formula (I) en suforma libre.It refers to addition salts with 10-aminoaliphatyl-dibenz [b, f] oxepine acids of formula (I), in which alk is a bivalent aliphatic radical, Res is an amino group unsubstituted, monosubstituted or disubstituted by aliphatic radicals and / or monovalent araliphatics or disubstituted by bivalent radicals aliphatics or araliphatics and R1, R2, R3 and R4 independently of each other denote hydrogen, lower alkyl, lower alkoxy, halogen otrifluoromethyl, with organic carboxylic acids. Said salts can be used as active substances for antineurodegenerative medicines. It also refers to the new compounds of formula (I) in their free form, to the use of said salts, to a process for making them, pharmaceutical preparations containing said salts or compounds of formula (I) in its free form and to a procedure for the treatment of neurodegenerative diseases using said salts or compounds of formula (I) in its free form.

ARP970102247A 1996-05-30 1997-05-27 AN ADDITION SALT WITH ACID OF A 10-AMINOALIFATIL-DIBENZ [B, F], OXEPINE, YOUR EMPLOYMENT; PROCEDURE FOR ITS PREPARATION, A 10-AMINOALIFATIL-DIBENZ [B, F] OXEPINE, A PHARMACEUTICAL PREPARATION CONTAINING SUCH SALT OR SUCH OXEPINE AND A PROCEDURE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AR008371A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH135296 1996-05-30

Publications (1)

Publication Number Publication Date
AR008371A1 true AR008371A1 (en) 2000-01-19

Family

ID=4208469

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970102247A AR008371A1 (en) 1996-05-30 1997-05-27 AN ADDITION SALT WITH ACID OF A 10-AMINOALIFATIL-DIBENZ [B, F], OXEPINE, YOUR EMPLOYMENT; PROCEDURE FOR ITS PREPARATION, A 10-AMINOALIFATIL-DIBENZ [B, F] OXEPINE, A PHARMACEUTICAL PREPARATION CONTAINING SUCH SALT OR SUCH OXEPINE AND A PROCEDURE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

Country Status (10)

Country Link
AR (1) AR008371A1 (en)
AU (1) AU3030397A (en)
CO (1) CO5080765A1 (en)
CZ (1) CZ296134B6 (en)
ID (1) ID18178A (en)
PE (1) PE70398A1 (en)
PL (1) PL191728B1 (en)
TR (1) TR199802482T2 (en)
WO (1) WO1997045422A1 (en)
ZA (1) ZA974802B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7355042B2 (en) 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
WO2003057204A2 (en) * 2002-01-08 2003-07-17 Nordic Bioscience A/S Modulation of iamt (pimt or pcmt) in immune system
JP2006516580A (en) * 2003-01-29 2006-07-06 ノバルティス アクチエンゲゼルシャフト Use of 10-aminoaliphatyl-dibenz [b, f] oxepin for the treatment of degenerative diseases of the eye
PE20050487A1 (en) * 2003-11-06 2005-10-07 Novartis Ag STABILIZED PHARMACEUTICAL COMPOSITIONS
WO2006034414A2 (en) 2004-09-21 2006-03-30 Hypnion, Inc. Loxapine analogs and methods of use thereof
US7563785B2 (en) 2004-10-29 2009-07-21 Hypnion, Inc. Quetiapine analogs and methods of use thereof
EP1757284A1 (en) 2005-08-25 2007-02-28 Santhera Pharmaceuticals (Schweiz) AG Use of N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy
EP1842539A1 (en) * 2006-04-05 2007-10-10 Santhera Pharmaceuticals (Schweiz) AG Use of N- (dibenz(b,f)oxepin-10-ylmethyl)N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency
WO2014120885A1 (en) 2013-01-30 2014-08-07 The Johns Hopkins University Treatment of drug abuse by preventing gapdh nitrosylation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3100207A (en) * 1959-07-08 1963-08-06 Smith Kline French Lab 10-aminoalkylbenzo[b,f]thiepin and -dibenz[b,f]oxepin derivatives
DE1493782B1 (en) * 1964-06-29 1969-12-11 Geigy Ag J R Basically substituted dibenzo [b, f] -oxepines and their non-toxic salts
CH585746A5 (en) * 1973-06-08 1977-03-15 Hoffmann La Roche
ATE203528T1 (en) * 1995-02-08 2001-08-15 Novartis Erfind Verwalt Gmbh ANTINEURODEGENERATIVELY EFFECTIVE 10-AMINOALIPHATYL-DIBENZ-B,F OXEPINE

Also Published As

Publication number Publication date
PL191728B1 (en) 2006-06-30
CZ387898A3 (en) 1999-02-17
TR199802482T2 (en) 1999-02-22
CZ296134B6 (en) 2006-01-11
WO1997045422A1 (en) 1997-12-04
AU3030397A (en) 1998-01-05
ID18178A (en) 1998-03-12
ZA974802B (en) 1998-11-30
PE70398A1 (en) 1998-11-09
PL330238A1 (en) 1999-05-10
CO5080765A1 (en) 2001-09-25

Similar Documents

Publication Publication Date Title
EE9900535A (en) Use of fumaric acid derivatives
ES2058527T3 (en) CONDENSED DERIVATIVES OF PIRIMIDINE PROCEDURE AND INTERMEDIATE COMPOUNDS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
ECSP034460A (en) NEW HETEROCICLIC COMPOUNDS, ITS PREPARATION AND ITS USE AS MEDICATIONS, IN SPECIAL AS ANTIBACTERIALS
ES2071621T3 (en) ALPHA DEXTROGYRAL ENANTIOMER- (TETRAHYDRO-4,5,6,7-TIENO- (3,2-C) -PIRIDIL-5) (CHLORINE-2-PHENYL) METHYL ACETATE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT.
BR0312513A (en) Thiophene glycoside derivatives, processes for their production, medicines containing these compounds and their use
ES2054860T5 (en) DERIVATIVES OF 9-HALOGEN- (Z) -PROSTAGLANDINAS, PROCEDURE FOR ITS PREPARATION AND ITS USE AS MEDICATIONS.
BR0111913A (en) Gabapentin analogs for sleep disorders
ES2170813T3 (en) 2,2-DICHLOROALCANOCARBOXILIC ACIDS, PROCESS FOR THEIR PREPARATION, MEDICINES CONTAINING THEM AND THEIR USE TO TREAT INSULIN RESISTANCE.
ES2186961T3 (en) BENZAZEPINONA-N-ACETIC ACID DERIVATIVES REPLACED BY PHOSPHONIC ACID, AS WELL AS PROCEDURE FOR THE PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS.
AR061765A2 (en) PROCESS FOR THE PREPARATION OF PRAVASTATIN SODIUM SALT IN A CRYSTAL FORM
ES2055035T3 (en) A PROCESS FOR THE PREPARATION OF AN ANTHRACICLINE GLYCOSIDE.
ATE10626T1 (en) N-SUBSTITUTED OMEGA-(2-OXO-IMIDAZOLINE-1-YL)ALKANES[URIENES, THEIR SALTS AND ESTERS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE ACTIVE SUBSTANCES.
AR008371A1 (en) AN ADDITION SALT WITH ACID OF A 10-AMINOALIFATIL-DIBENZ [B, F], OXEPINE, YOUR EMPLOYMENT; PROCEDURE FOR ITS PREPARATION, A 10-AMINOALIFATIL-DIBENZ [B, F] OXEPINE, A PHARMACEUTICAL PREPARATION CONTAINING SUCH SALT OR SUCH OXEPINE AND A PROCEDURE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
AR045793A1 (en) COMPOUNDS DERIVED FROM 3-HETEROCICLIL-INDOL
AR013462A1 (en) NEW PEPTIDOMIMETICOS FOR THE TREATMENT OF BONE DISORDERS, METHODS FOR ITS PRODUCTION AND DRUGS THAT CONTAIN THESE COMPOUNDS
BR9916669A (en) Use of derivatives of substituted 4-biarylbutyric and 5-biarylpentanoic acids as matrix metalloprotease inhibitors for the treatment of respiratory diseases
ES2071666T3 (en) DERIVATIVES OF PIRAZOLOISOQUINOLINE, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
BR9507231A (en) Use of carboxylic acid derivatives for drug production
BR0111933A (en) Use of pamic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterized by deposits of amyloid aggregates
BR0010225A (en) Amide compound, process for preparing it, pharmaceutical composition comprising said compound, method of treatment and use
ES2043070T3 (en) PROCEDURE FOR THE PREPARATION OF BENZOTIAZOLAMINE-2 DERIVATIVES.
ES2147196T3 (en) PROCEDURE FOR THE STEREO-SPECIFIC HYDROLYSIS OF DERIVATIVES OF PIPERIDINDIONA.
ECSP045192A (en) "STABLE SALTS OF O-ACETILSALICILIC ACID WITH BASIC AMINO ACIDS II"
DK429480A (en) PHOSPHONO HYDROXYDIC ACETIC ACID PROCEDURES FOR PREPARING IT AND USING IT AS A MEDICINE
MX9400165A (en) DERIVATIVES OF TER-BUTYLERGOLINE, PROCESS FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.